Renin-angiotensin system: Meta-analyses can misdirect decisions on treatment

Nature Reviews Nephrology

Volumn 9, Issue 6, 2013, Pages 311-312

  Ruggenenti, Piero ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; POTASSIUM;

CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CLINICAL DECISION MAKING; CREATININE BLOOD LEVEL; DEATH; DIABETES MELLITUS; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; META ANALYSIS (TOPIC); MONOTHERAPY; NONHUMAN; PERIPHERAL VASCULAR DISEASE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; SHORT SURVEY; TRANSIENT ISCHEMIC ATTACK;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; MALE; RENIN-ANGIOTENSIN SYSTEM;

EID: 84878599535     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2013.82     Document Type: Short Survey

References (10)

1. Makani, H., Bangalore, S., Desouza, K. A., Shah, A. & Messerli, F. H. Efficacy and safety of dual blockade of the renin-angiotensin system: Meta-analysis of randomised trials. BMJ http://dx.doi.org/10.1136/bmj.f360.
2. Werner, C. et al. RAS blockade with ARB and ACE inhibitors: Current perspective on rationale and patient selection. Clin. Res. Cardiol. 97, 418-431 (2008).
3. Ruggenenti, P., Cravedi, P. & Remuzzi, G. Mechanisms and treatment of CKD. J. Am. Soc. Nephrol. 23, 1917-1928 (2012).
4. Menard, J., Campbell, D. J., Azizi, M. & Gonzales, M. F. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats. Circulation 96, 3072-3078 (1997).
5. Zoja, C. et al. How to fully protect the kidney in a severe model of progressive nephropathy: A multidrug approach. J. Am. Soc. Nephrol. 13, 2898-2908 (2002).
6. McMurray, J. J. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting enzyme inhibitors: The CHARM-Added trial. Lancet 362, 767-771 (2003).
7. Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213-1224 (2008).
8. Parving, H. H. et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204-2213 (2012).
9. Sever, P Hypotension and ischaemic stroke associated with aliskiren in the ALTITUDE trial: Sensitisation of the Bezold-Jarisch reflex? J. Renin Angiotensin Aldosterone Syst. 14, 1-2 (2013).
10. Cravedi, P., Ruggenenti, P. & Remuzzi, G. Proteinuria should be used as a surrogate in CKD. Nat. Rev. Nephrol. 8, 301-306 (2012).